Total Compensation: $13.599 million
Professional Profile: Dr. Bell, 54, is actually one of the scientists who developed Soliris, the rare-disease drug that is Alexion's ($ALXN) bread and butter and the most expensive treatment in the world. Before co-founding Alexion in 1992, Bell was an assistant professor of medicine and pathology at Yale University School of Medicine, where he also attended medical school. He's still on the faculty there as an adjunct assistant professor. Bell took Alexion through an IPO in 1996.
Compensation Breakdown: $1.1 million in salary, $2.84 million in stock, and $6.84 million worth of options, plus $2.8 million in incentive pay and $15,021 in other compensation.
Company Performance: Alexion started 2012 with a new asset in its pocket. As 2011 came to a close, the company had wrapped up a deal for the Canadian biotech, Enobia, and its in-development treatment for hypophosphatasia, with $610 million up front and the promise of $470 million in milestone payments. The buyout was an important step toward diversifying Alexion's lineup beyond the very successful rare-disease drug Soliris, which is now approved in 40 countries. By June, the company had made plans for a new headquarters in New Haven, CT, to house its fast-growing staff. Then, in October, new data showed Soliris' benefits in another rare disease--relapsing neuromyelitis optica--a step toward a new indication for that drug. Soliris ended the year with $1.13 billion in sales, a 45% increase.
Pricey Soliris performs in another rare disease
Now, every pharma wants a $440K drug like Alexion's
Booming Alexion blueprints new HQ, plans for 300 new hires
R&D success puts Alexion at the top of the M&A list
Alexion scoops up rare disease drug in $1.08B Enobia buyout